Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.45 |
| ▸ | NAAA | Q02083 | 8/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908124 | 0.79 | KDM4E (0.49) | FAAHNAAAMEN1KMT2ANPSR1 | |
| SCHEMBL27244877 | 0.78 | FAAH (0.37) | FAAHNAAAKDM4E | |
| SCHEMBL27244869 | 0.78 | FAAH (0.37) | FAAHNAAAKDM4E | |
| SCHEMBL908487 | 0.73 | LMNA (0.55) | FAAHNAAAMEN1KMT2ANPSR1 | |
| SCHEMBL27504573 | 0.73 | IDO1 (0.55) | KMT2ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL25597938 | 0.73 | IDO1 (0.55) | KMT2ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL14190212 | 0.73 | IDO1 (0.55) | KMT2ASMN1; SMN2NPC1RAB9ACYP2C19 | |
| SCHEMBL24535126 | 0.72 | MEN1 (0.44) | FAAHNAAAMEN1KMT2ANPSR1 | |
| SCHEMBL11681599 | 0.72 | NAAA (0.60) | FAAHNAAAMEN1KMT2ANPSR1 | |
| Hydrochloric Acid SCHEMBL3820370 | 0.72 | IDO1 (0.54) | KMT2ASMN1; SMN2NPC1RAB9ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612156-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-20 | — | — | US | disclosed |
| WO-2024097296-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199647-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | FAAH 3236/4885NAAA 2502/4885MEN1 1494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.